Stock Analysis
- Canada
- /
- Commercial Services
- /
- TSXV:BRM
BioRem Second Quarter 2024 Earnings: EPS: CA$0.021 (vs CA$0.006 loss in 2Q 2023)
BioRem (CVE:BRM) Second Quarter 2024 Results
Key Financial Results
- Revenue: CA$7.30m (up 71% from 2Q 2023).
- Net income: CA$339.8k (up from CA$96.5k loss in 2Q 2023).
- Profit margin: 4.7% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue.
- EPS: CA$0.021 (up from CA$0.006 loss in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
BioRem shares are up 2.3% from a week ago.
Risk Analysis
Before we wrap up, we've discovered 1 warning sign for BioRem that you should be aware of.
Valuation is complex, but we're here to simplify it.
Discover if BioRem might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSXV:BRM
BioRem
A clean technology engineering company, designs, manufactures, distributes, and sells air pollution control systems that are used to eliminate odors, volatile organic compounds (VOCs), and hazardous air pollutants (HAPs).